S&P 500   4,184.05 (+0.10%)
DOW   32,850.62 (-0.18%)
QQQ   347.39 (-0.17%)
AAPL   177.88 (+0.36%)
MSFT   326.92 (-0.45%)
META   269.64 (+1.86%)
GOOGL   123.15 (+0.23%)
AMZN   120.58 (+0.00%)
TSLA   200.87 (-1.50%)
NVDA   386.80 (+2.24%)
NIO   7.23 (-3.98%)
BABA   81.20 (+2.07%)
AMD   118.00 (-0.18%)
T   15.70 (-0.19%)
F   11.95 (-0.42%)
MU   68.12 (-0.12%)
CGC   0.82 (-1.77%)
GE   103.27 (+1.71%)
DIS   87.73 (-0.26%)
AMC   4.55 (+1.11%)
PFE   38.07 (+0.13%)
PYPL   62.59 (+0.97%)
NFLX   401.11 (+1.49%)
S&P 500   4,184.05 (+0.10%)
DOW   32,850.62 (-0.18%)
QQQ   347.39 (-0.17%)
AAPL   177.88 (+0.36%)
MSFT   326.92 (-0.45%)
META   269.64 (+1.86%)
GOOGL   123.15 (+0.23%)
AMZN   120.58 (+0.00%)
TSLA   200.87 (-1.50%)
NVDA   386.80 (+2.24%)
NIO   7.23 (-3.98%)
BABA   81.20 (+2.07%)
AMD   118.00 (-0.18%)
T   15.70 (-0.19%)
F   11.95 (-0.42%)
MU   68.12 (-0.12%)
CGC   0.82 (-1.77%)
GE   103.27 (+1.71%)
DIS   87.73 (-0.26%)
AMC   4.55 (+1.11%)
PFE   38.07 (+0.13%)
PYPL   62.59 (+0.97%)
NFLX   401.11 (+1.49%)
S&P 500   4,184.05 (+0.10%)
DOW   32,850.62 (-0.18%)
QQQ   347.39 (-0.17%)
AAPL   177.88 (+0.36%)
MSFT   326.92 (-0.45%)
META   269.64 (+1.86%)
GOOGL   123.15 (+0.23%)
AMZN   120.58 (+0.00%)
TSLA   200.87 (-1.50%)
NVDA   386.80 (+2.24%)
NIO   7.23 (-3.98%)
BABA   81.20 (+2.07%)
AMD   118.00 (-0.18%)
T   15.70 (-0.19%)
F   11.95 (-0.42%)
MU   68.12 (-0.12%)
CGC   0.82 (-1.77%)
GE   103.27 (+1.71%)
DIS   87.73 (-0.26%)
AMC   4.55 (+1.11%)
PFE   38.07 (+0.13%)
PYPL   62.59 (+0.97%)
NFLX   401.11 (+1.49%)
S&P 500   4,184.05 (+0.10%)
DOW   32,850.62 (-0.18%)
QQQ   347.39 (-0.17%)
AAPL   177.88 (+0.36%)
MSFT   326.92 (-0.45%)
META   269.64 (+1.86%)
GOOGL   123.15 (+0.23%)
AMZN   120.58 (+0.00%)
TSLA   200.87 (-1.50%)
NVDA   386.80 (+2.24%)
NIO   7.23 (-3.98%)
BABA   81.20 (+2.07%)
AMD   118.00 (-0.18%)
T   15.70 (-0.19%)
F   11.95 (-0.42%)
MU   68.12 (-0.12%)
CGC   0.82 (-1.77%)
GE   103.27 (+1.71%)
DIS   87.73 (-0.26%)
AMC   4.55 (+1.11%)
PFE   38.07 (+0.13%)
PYPL   62.59 (+0.97%)
NFLX   401.11 (+1.49%)
NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Forecast, Price & News

$0.21
+0.00 (+0.05%)
(As of 10:21 AM ET)
Compare
Today's Range
$0.20
$0.22
50-Day Range
$0.14
$0.22
52-Week Range
$0.10
$2.20
Volume
84,187 shs
Average Volume
3.11 million shs
Market Capitalization
$14.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Vascular Biogenics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2,520.3% Upside
$5.50 Price Target
Short Interest
Healthy
1.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.50mentions of Vascular Biogenics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

877th out of 1,006 stocks

Pharmaceutical Preparations Industry

439th out of 492 stocks


VBLT stock logo

About Vascular Biogenics (NASDAQ:VBLT) Stock

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
See More Headlines

VBLT Price History

VBLT Company Calendar

Last Earnings
3/14/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$5.50
Forecasted Upside/Downside
+2,520.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-32,300,000.00
Net Margins
-4,465.93%
Pretax Margin
-4,498.17%

Debt

Sales & Book Value

Annual Sales
$660,000.00
Book Value
$0.29 per share

Miscellaneous

Free Float
65,474,000
Market Cap
$14.64 million
Optionable
Optionable
Beta
0.68

Key Executives

  • Dror Harats
    Chief Executive Officer & Director
  • Eyal Breitbart
    Senior Vice President-Research & Operations
  • Erez Feige
    Senior Vice President-Business Operations
  • Samuel I. Backenroth
    Chief Financial Officer
  • Amos Ron
    Secretary













VBLT Stock - Frequently Asked Questions

Should I buy or sell Vascular Biogenics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" VBLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VBLT, but not buy additional shares or sell existing shares.
View VBLT analyst ratings
or view top-rated stocks.

What is Vascular Biogenics' stock price forecast for 2023?

3 brokers have issued 12 month target prices for Vascular Biogenics' stock. Their VBLT share price forecasts range from $5.50 to $5.50. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 2,520.3% from the stock's current price.
View analysts price targets for VBLT
or view top-rated stocks among Wall Street analysts.

How have VBLT shares performed in 2023?

Vascular Biogenics' stock was trading at $0.12 at the beginning of the year. Since then, VBLT stock has increased by 74.9% and is now trading at $0.2099.
View the best growth stocks for 2023 here
.

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a increase in short interest in May. As of May 15th, there was short interest totaling 812,500 shares, an increase of 117.1% from the April 30th total of 374,200 shares. Based on an average daily volume of 4,180,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.5% of the shares of the company are short sold.
View Vascular Biogenics' Short Interest
.

When is Vascular Biogenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VBLT earnings forecast
.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) announced its quarterly earnings data on Tuesday, March, 14th. The biopharmaceutical company reported ($0.05) EPS for the quarter. Vascular Biogenics had a negative net margin of 4,465.93% and a negative trailing twelve-month return on equity of 96.11%.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Belvedere Trading LLC (0.00%).

How do I buy shares of Vascular Biogenics?

Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $0.21.

How much money does Vascular Biogenics make?

Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $14.64 million and generates $660,000.00 in revenue each year. The biopharmaceutical company earns $-32,300,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001.

This page (NASDAQ:VBLT) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -